Media

Follow our progress and stay up to date with our press releases and media coverage.

Press Releases

GeneVentiv Therapeutics Expands Scientific Advisory Board

GeneVentiv Therapeutics Expands Scientific Advisory Board

March 3, 2021 Damon R. Race, President & CEO RALEIGH, NC – GeneVentiv Therapeutics, a gene therapy company developing a safe, effective, and durable, single infusion treatment for all types of hemophilia with or without inhibitors, today announced the expansion of...

read more
Geneventiv Therapeutics Licenses Gene Therapy for Hemophilia

Geneventiv Therapeutics Licenses Gene Therapy for Hemophilia

GeneVentiv Therapeutics and University of North Carolina Chapel Hill Enter License Agreement RALEIGH, NC, November 2, 2020 — GeneVentiv Therapeutics, Inc. has entered into a license agreement with the University of North Carolina Chapel Hill for a patent pending, gene...

read more

In the News

Potential Gene Therapy GENV-HEM Earns Orphan Drug Status

Potential Gene Therapy GENV-HEM Earns Orphan Drug Status

Hemophilia News Today by Marta Figueiredo PhD | November 3, 2021 The U.S. Food and Drug Administration (FDA) has granted orphan drug designation to GENV-HEM, GeneVentiv Therapeutics’ investigational gene therapy for hemophilia A and B patients, with or without...

read more
UNC Gene Therapy Spinoff Aims to Cure Hemophilia

UNC Gene Therapy Spinoff Aims to Cure Hemophilia

Latest spinoff from UNC’s Gene Therapy Center wants to find a cure for hemophilia Read more here: https://www.newsobserver.com/news/business/article247379109.html#storylink=cpy RALEIGH UNC-Chapel Hill’s gene therapy center has birthed yet another startup in the...

read more